<SEC-DOCUMENT>0001104659-25-009125.txt : 20250204
<SEC-HEADER>0001104659-25-009125.hdr.sgml : 20250204
<ACCEPTANCE-DATETIME>20250204162115
ACCESSION NUMBER:		0001104659-25-009125
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250204
DATE AS OF CHANGE:		20250204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Transcode Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001829635
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				811065054
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40363
		FILM NUMBER:		25588548

	BUSINESS ADDRESS:	
		STREET 1:		6 LIBERTY SQUARE
		STREET 2:		#2382
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		857-301-6857

	MAIL ADDRESS:	
		STREET 1:		6 LIBERTY SQUARE
		STREET 2:		#2382
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm255410d2_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section&nbsp;14(a)&nbsp;of
the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by the Registrant</FONT>&#8239;<FONT STYLE="font-family: Wingdings">&#120;</FONT> Filed by a Party other than the Registrant <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 1%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; vertical-align: bottom; width: 99%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0in">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0in">&#8239;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Additional Materials</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TransCode Therapeutics,&#8239;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s)&nbsp;Filing Proxy Statement,
if other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fee required. </FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee paid previously with preliminary materials. </FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee computed on table in exhibit required by Item 25(b)&nbsp;per
    Exchange Act Rules&nbsp;14a-6(i)(1)&nbsp;and 0-11 </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm255410d2_defa14aimg001.jpg" ALT=""></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>TransCode
Therapeutics,&nbsp;Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">---</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BOSTON, February&nbsp;4, 2025 (GLOBE NEWSWIRE)
-- TransCode Therapeutics,&nbsp;Inc. (Nasdaq: RNAZ) (&ldquo;TransCode&rdquo; or the &ldquo;Company&rdquo;), the RNA Oncology Company&trade;
committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on
February&nbsp;4, 2025 (the &ldquo;Special Meeting&rdquo;) has been adjourned until February&nbsp;25, 2025 at 9:30 a.m.&nbsp;Eastern time
(the &ldquo;Adjourned Special Meeting&rdquo;) for the purpose of soliciting additional votes with respect to the proposals outlined below
and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the
 &ldquo;SEC&rdquo;) on December&nbsp;30, 2024 (the &ldquo;Special Meeting Proxy Statement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The presence, by remote communication or by proxy,
of the holders of at least one-third of the outstanding shares of capital stock entitled to vote at the meeting will constitute a quorum.
There was less than that number of shares represented at the Special Meeting, so a quorum did not exist. At the time the Special Meeting
was adjourned, proxies had been submitted by stockholders representing approximately 29.94% of the outstanding shares of stock entitled to
vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposal One</B> is a
                                                                                                                                                                                                                 proposal to approve (i)&nbsp;for purposes of complying with Nasdaq Listing Rule&nbsp;5635(d), the full issuance of shares of Common
                                                                                                                                                                                                                 Stock by the Company upon exercise of the Series&nbsp;C Warrants and the Series&nbsp;D Warrants (both as defined in the Special
                                                                                                                                                                                                                 Meeting Proxy Statement), (ii)&nbsp;a series of adjustments to the exercise price of the Warrants and an increase in the underlying
                                                                                                                                                                                                                 Common Stock of the Warrants, (iii)&nbsp;an alternative cashless exercise feature in the Series&nbsp;D Warrants and (iv)&nbsp;an
                                                                                                                                                                                                                 adjustment to the exercise price and number of Warrants upon the Shareholder Approval Date (as defined in the Special Meeting Proxy
                                                                                                                                                                                                                 Statement) and possibly at other times, subject to a floor price of $2.4882 (the &ldquo;Issuance Proposal&rdquo; or &ldquo;Proposal
                                                                                                                                                                                                                 1&rdquo;)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposal
Two </B>is a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation
and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Issuance
Proposal (the &ldquo;Adjournment Proposal&rdquo; or &ldquo;Proposal 2&rdquo;)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Adjournment of Special Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Adjourned Special Meeting will be reconvened
on February&nbsp;25, 2025, at 9:30 a.m.&nbsp;Eastern Time and will continue to be held in a virtual format and stockholders will be able
to listen and participate in the virtual special meeting, as well as vote and submit questions during the live webcast of the meeting
by visiting&nbsp;www.virtualshareholdermeeting.com/RNAZ2025SM&nbsp;and entering the 16 digit control number included in your proxy card.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TransCode encourages eligible stockholders as
of the record date of December&nbsp;17, 2024, who have not yet voted their shares on Proposal One or Proposal Two or are uncertain if
their shares have been voted on Proposal One or Proposal Two to contact their broker or bank to vote their shares. The Board of Directors
and management request that these stockholders consider and vote their proxies as soon as possible on Proposal One and Proposal Two, but
no later than February&nbsp;24, 2025, at 11:59 p.m.&nbsp;Eastern time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stockholders who have previously submitted their
proxy or otherwise voted on Proposal One and Proposal Two at the Special Meeting and who do not want to change their vote need not take
any action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described in the Special Meeting Proxy Statement,
stockholders may use one of the following simple methods to vote their shares, or change their previously submitted vote, before the February&nbsp;25,
2025, Adjourned Special Meeting with respect to Proposal One or Proposal Two:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>By mail</I>. Complete and
mail the proxy card in the postage prepaid envelope. Your proxy will be voted in accordance with your instructions. If you sign the proxy
card but do&nbsp;not specify how you want your eligible shares voted, they will be voted as recommended by our Board. Your proxy card
must be received on or before 11:59 P.M.&nbsp;Eastern time on February&nbsp;24, 2025, the day before the Adjourned Special Meeting, to
be counted.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In attendance at the Adjourned
Special Meeting</I>. You may vote during the virtual meeting through www.virtualshareholdermeeting.com/RNAZ2025SM. To be admitted to the
Special Meeting and vote your eligible shares, you must provide the control number as described in the proxy card previously mailed to
you.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Over the Internet</I>. You
may submit your proxy to vote via the Internet by going to www.proxyvote.com and following the on-screen instructions. Please have your
proxy card available when you access the webpage. Your proxy to vote must be received prior to 11:59 P.M.&nbsp;Eastern time on February&nbsp;24,
2025, the day before the Adjourned Special Meeting, to be counted.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>By telephone</I>. You may
vote over the telephone by calling toll-free 1-800-690-6903 in the U.S. and following the recorded instructions. Please have your proxy
card available when you call. Your vote must be received prior to 11:59 P.M.&nbsp;Eastern time on February&nbsp;24, 2025, the day before
the Adjourned Special Meeting, to be counted</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Votes must be received by 11:59 p.m.&nbsp;Eastern
time on February&nbsp;24, 2025, to be counted. After this time, votes can only be cast during the Adjourned Special Meeting on February&nbsp;25,
2025, at 9:30 a.m.&nbsp;Eastern Time at&nbsp;www.virtualshareholdermeeting.com/RNAZ2025SM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About TransCode Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TransCode is a clinical-stage oncology company focused on treating
metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics
based on its proprietary TTX nanoparticle platform. The Company&rsquo;s lead therapeutic candidate, TTX-MC138, is focused on treating
metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio
of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access
to a variety of novel genetic targets that could be relevant to treating a variety of cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains
 &ldquo;forward-looking statements&rdquo; as defined by the Private Securities Litigation Reform Act of 1995 that involve risks and
uncertainties. In some cases, you can identify forward-looking statements by terms such as &ldquo;believe,&rdquo; &ldquo;can,&rdquo;
 &ldquo;could,&rdquo; &ldquo;design,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo;
 &ldquo;might,&rdquo; &ldquo;objective,&rdquo; &ldquo;plan&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
 &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; or the negative of these terms and similar expressions intended to
identify forward-looking statements. These forward-looking statements include statements related to the Issuance Proposal and
Adjournment Proposal, the future, the timing and outcome of the Adjourned Special Meeting, matters described above, the
parties&rsquo; expectations and related matters. TransCode cautions readers that forward-looking statements are based on
management&rsquo;s expectations and assumptions as of the date of this press release and are subject to certain risks and
uncertainties that could cause actual results to differ materially and adversely from those expressed in, or implied by, these
forward-looking statements, including, but not limited to, the timing of the Adjourned Special Meeting. These and other risks and
uncertainties are described more fully in the sections titled &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Note Regarding
Forward-Looking Statements&rdquo; in the Company&rsquo;s annual report on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q and
other reports filed with the SEC. Forward-looking statements reflect the Company&rsquo;s analysis only on their stated date, and
TransCode undertakes no obligation to update or revise these statements except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information and Where to Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the solicitation of proxies,
on December&nbsp;30, 2024, TransCode filed the Special Meeting Proxy Statement with the SEC with respect to the Special Meeting. Promptly
after filing the Special Meeting Proxy Statement with the SEC, TransCode mailed the Special Meeting Proxy Statement and a proxy card
to each stockholder entitled to vote at the Special Meeting to consider the proposals. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT
(INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT TRANSCODE HAS FILED OR WILL FILE WITH THE SEC
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, the Special Meeting Proxy Statement, any amendments
or supplements thereto, and any other relevant documents filed by TransCode with the SEC in connection with the proposals at the SEC's
website (<U>http://www.sec.gov</U>) or at the Company's investor relations website (<U>https://ir.transcodetherapeutics.com/</U>). The
information provided on, or accessible through, our website is not part of this communication, and therefore is not incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">TransCode Therapeutics,&nbsp;Inc.<BR>
Tania Montgomery-Hammon<BR>
VP Business Development<BR>
Tania.montgomery@transcodetherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm255410d2_defa14aimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm255410d2_defa14aimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !# 9 # 2(  A$! Q$!_\0
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MTJY77]6TK338PZEJ=OIGV^]-M9"6Y\I[ZZW$O;(AP9,Y!=4W8!Z =>H7H?\
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M"UW7O$>C:-I6G27+311:K;3:[#IE]K2HYA$UCI%QI0MP^U8;E$EB[&T\*?\
M!U'\*_\ 2CXW^"OQ7TF$EWTBY_X5EK$MXEOT@!O?"&HZZ9)=N6%OJ$,I^8":
M/&X?2?PT_P"#D/X!-I5K9_M'?L^?'SX'>,K;9#J.FW7@W5M7TN&[CF"3-;32
M6T#6T8C#A?,!.WY0?F&?3+__ (.,_P#@GT(3'HMO\8?$TZ70D@L=%^'-Q>:B
MUQN#1"V@N=L0='PS,NZ5%!,89P ?I\/B\UJM*>79;F5%:.KB:N'5162_=*]:
M,N5*TEK?WFKJUEY\H8>#LL37PUW?V<(SY7O[^D&K[Q[Z'S?\-/\ @NW^TO\
M KXQ> ?@%_P5!_9"O_@'K?C;4+#2](^*GA2#4+#PX8[F=;*+79])UO4=4M[V
MSENG,+W%A)9VD4C@"%2-@_J!T2XAO+475LB);S;IX K/*3#.[ 227&/*,TKQ
M.;FU0[K.9?(E&Y17\3_QTD_:O_X+O_M1_ ?4?#'[,GC;X+_LF_!KQ3%)J/C7
MQUIC67B6]TA==AU"^OVUC4;2UU&V;45MK:2WTJW,EHL:?.[.JD_VPZ)#!!!&
ML(_=16UO8([H8Y3#8@I$9#C$AF\V64R +EN<$GY>#/<-3<*=2.$PF!JN*<L+
MA*L*M--7_>6C4JN,JC>L;Z*&ENO70Y?9WC6G67,_?J)J73W=5%M+O;KN7=3R
M\<80YVR;G5)9HI&48_=J\$<CJ)"0I^Z6'W2:_./]GCP[^Q_!^T?\;+[X8:I/
MJ_QZAFNK;XC?VS<W6KZGIVJ"2:X=-)&I1+)']FMY"D2V>2R*RRX$<=?HU<)"
M\D1E4G$JM$=Q5=P4 EL=0,8P>,XR*_$+]L']E?XZ_#'X_C]L#]DNRD?7[V&+
M4/&_A6"2:2'5KBT*QW,,VC09DU0ZG;LZN8P3;*@8_P"N KAR^JIPG0DU"7+I
M=J+=UV;3M\MKV>QQXZFXNG746[-)M1;^'2][6MZO?H?MR(<R$LIRYC57+ BX
M41@+/@ !97.\3?)G"J5RH!%SR]A'^L!V8P@+=R 2%#8P>V.,8))SG\<?AY_P
M5A\,:=9OI7Q^^#OCSX6>*[& _;+>R\/ZC?Z'+=(=LIM//B273V#<O!(6+F52
MI!C8MVFN?\%:_@);V4\GA'PM\2/&NI>0)$TS3?#5W$9F*\H9EBE*2%OEY7.T
MDCI64LMK.4G&<8Q;;2<HIK7_ !+[[+>^O4>94592A*322;2;6RZZ].VQ^J<=
MO%$SD-\Q9I6WD;ER #N'8 !<YP!Z#G-ESF-BOS KD;><@XP1CJ.<Y]*^!/V0
MOVG?CI^T%K7BG4/B)\"-5^%7P^-M#+X%UF_%U)=ZIN*,T5]YR)Y=R(GWO#Y8
MV*(I"<2D5]^*H6-\ X()+'N3MR>O&3_"/R%95Z;IP5)M2E!<LG'WKO?2U]-3
M?#S53FJ1BU&I=Q4DT[-^GD_ZN?SY_P#!9B?/Q%_90LM;\Q?"EQK7B4WT4K[=
M.:Q76/!*>)=1O&?;! ^G^&)];BDEE<+':2M)*R1$FOWB\/V^F6N@:-%I)L_[
M'M]&TU=-:-XUB&F&TB^Q2# *A);;RWWYV2$EP3D ?'W[=/[)6G?M<?"=?""W
M_P#8?C#PSJ!\1>"]<1 SI>[9(=1TJ=QEEL=5MEMHYU0@-Y0W;AG;\!?!+]NS
MXX?LQV.B_!O]KGX.>+9H_"-G%I%G\4/"^DWVJ"YM;0#;YMJMLZS0RQ.DD,GV
M@!;=DS]Q57T:\JF)RC 4,/5C2JT:T5.,IQBTK1]ZTG%I:?$U;=-H\VG[##8W
M%5<1%SC.M4FK+F:O)6325U;Y>=S]X8U38N0 6'&<8)ST4DX.1C&, \XZ$#X6
M_P""AUCX7N?V2/CE-XB&F+'9^'X[O3Y-1\N0V/BB*[BAT>]TV:8K'%J,]HS1
MR109FC@91CYG9O*KO_@J_P#LSQ6EQ)IDWBW5=3\EY;+1+3PY<QW-U+@[896V
ML8YV("E=ORG(.2#7PM\6->_:H_X*:^(/#/@_PC\/]:^%G[.>C^(;?4O$.L:[
M]JTV]UJ."8&\M)_/CB6Y7RE;[(NW820RCYCEX+"8J%63Q=:G*#G)K]Y3=H\S
M:5U-IJUE=-KJFUN8K&86I?ZK2G";N[N$H:ZV>J5KW[[=C]*O^"9IU5_V,O@Y
M-??:$SIFJOI:3!W5-).KW$"0H3]V+[3!>7,:CY1',K+A7Y^_+CDA5P3A>..G
MS]OQ!'![>U>>?";P+HGPQ^'GA/X?^&('CT+P=HMMX>T\.H\R6&&&&62Z?!&9
M);B6<R'',HD.>P]"F5O,^521E0#[#ICGCGG_ .O7GXJ4,1C&G**BG)7YHVTD
MUO>W33738]/#7PV$6C<G%2Y8IW]Y)[+7KKU?G<_!K_@KRRCXU_L: X4CQ-?$
MJQ"G">(M D<D9#81"'<X^5&#$@'-?NQIXS;69/&ZRA XR#_HEJ./7.2.IXK\
M*O\ @L+::X/B-^R7XHT?P_K&O1>&-5\07>IQZ1IUUJ#10B[T*>)Y1:QR;?-6
MUG,1;&XHX!P.?>+?_@K!\-(HHK>3X._&>9K6W@2>:+PAJ;0W,OD6V3;?Z-S&
M'#*V,?=/!Q7JUZ-/&97E$8SA*=.G+FC&<'.#MHIQ4W*%V_M*+^9Y6&K2PV9Y
MO+DER3J1<9<L^2>L6W"2C::M_*Y>>A^LER;<1^8T\:(L@5Y"ZGRW)'& ?FD7
MJ$X).-JDY%?!'_!1RU\$K^R/\6)?%UKIKA=*:/2I=3>#[7'J3ZBCQM8FX97M
M[E8V,R% '$7S8"G)^>O$G_!6G0C8&'PI^SM\8/$VJR;H[:PNM%U#1K)W/$$9
MF>S=G=W*QX"$Y("C)(KY=\1^"?VRO^"EOBGPW;?$CP9??!7X Z/=PW<VG3?;
MM.:YD#G]^FG7BQ7%_?)$2IE?,!7?Y<:K@#+ X*OA:M+$2J12H5(5K.<$W[*<
M:MDG*[O[.WKI:YTXK&T<1"6'4)MUHRH<SC*R]JG3NVHM)+G^Y7;W/TE_X)J-
MKDW[&?P*DU87<H?PFDEG-=>:+@Z=!,+?3"Z2(";:XMRTEG(/DFC4RQ%T&ZOT
M!E DB=,DY4A@H)?[G\(&3N!!P!DYXYKB_ 'A#0O OA3PIX-\.6YM-!\-:9'H
M.F6OEB(I:V5NJ6[&,!,+M21B"!\TV1G-=X8E3Y@HSQVZ$\8'/&/ZGI7)F-65
M;%U<5%VE6<E?1*/-+XI.[M;1WNO-Z,[<+35#"TL,TW&ARO:]U%WLK+K;9=-M
M;'\[_P#P6$TK6M2^-W[+&D>&M4_L37=8\5V&E:!KDLUQ;SZ9KVI>(M#L]&O4
M-M/:W#QVVHR03E0^QC"2P8IE?6S^QC_P4N3:8?VW0T9"[BR:\CHPM+*!QM.K
M@LDMW:WTJ2GAPVY2=V:X7_@K:/$6G?'#]EOQGIOAKQ#K^G>"?$FE>)-1&AZ3
M=:G)Y6B^*-$U&6("VCD"2&.V>3<Q!"Q,>U?18_X*R?#*)%7_ (4I\:]P>:*4
M)X1O7),*P2QR(+FW">1+)>W@C92&+0L!QN ]^LL4\'@7%4Z\4E>#E%QEIM+W
MK<K>OE97MI?P,-AL)/&8W$3A5I*GS3YXPFI05TG)>[=OWDM+[OLSS ?L:_\
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MN(=-TC1OBWIC:KJ>H2&WL=+@O;66VAEU.\;_ $>UB\VW;S;^[DBA@0HK.?.
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(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
